Synergistic Enteral Regimen for Treatment of the Gangliosidoses (Syner-G)
Synergistic Enteral Regimen for Treatment of the Gangliosidoses (Syner-G)
Sponsor: Lysosomal Disease Network
Terminated
Efficacy
Listed as NCT02030015, this PHASE4 trial focuses on GM1 Gangliosidoses and GM2 Gangliosidoses and remains terminated or withdrawn. Sponsored by Lysosomal Disease Network, it has been updated 15 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
15 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Oct 2022 — Jul 2024 [monthly]
Terminated PHASE4
-
May 2021 — Oct 2022 [monthly]
Terminated PHASE4
Status: Recruiting → Terminated
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE4
▶ Show 10 earlier versions
-
Nov 2019 — Jan 2021 [monthly]
Recruiting PHASE4
-
Jun 2019 — Nov 2019 [monthly]
Recruiting PHASE4
-
Jan 2019 — Jun 2019 [monthly]
Recruiting PHASE4
-
Sep 2018 — Jan 2019 [monthly]
Recruiting PHASE4
-
Jul 2018 — Sep 2018 [monthly]
Recruiting PHASE4
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE4
-
Nov 2017 — Jun 2018 [monthly]
Recruiting PHASE4
Status: Active Not Recruiting → Recruiting
-
Sep 2017 — Nov 2017 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Sep 2017 [monthly]
Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE4
First recorded
Dec 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Lysosomal Disease Network
- National Center for Advancing Translational Sciences (NCATS)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Institute of Neurological Disorders and Stroke (NINDS)
- Rare Diseases Clinical Research Network
- University of Minnesota
For direct contact, visit the study record on ClinicalTrials.gov .